Reported Earlier, Quest Diagnostics Prices $1.85B Senior Notes Due 2027, 2029, And 2034
Author: Benzinga Newsdesk | August 16, 2024 03:14am
Quest Diagnostics Incorporated (NYSE:DGX) (the "Company"), a leader in diagnostic information services, today announced the pricing of a public offering of $400 million aggregate principal amount of its 4.600% senior notes due 2027 (the "2027 notes"), $600 million aggregate principal amount of its 4.625% senior notes due 2029 (the "2029 notes") and $850 million aggregate principal amount of its 5.000% senior notes due 2034 (the "2034 notes," and together with the 2027 notes and the 2029 notes, the "notes") under Quest Diagnostics' shelf registration statement.
Posted In: DGX